Volume9

Background: Tuberculosis is the most prevalent infectious disease in India. DOTS treatment under NTEP (Previously RNTCP) has been the mainstay to control and reduce its burden on our country. In 2017, daily treatment regimen was introduced by DOTS replacing the alternate day regimen. In January 2020, the name RNTCP (Revised National Tuberculosis Control Program) was replaced by NTEP (National Tuberculosis Elimination Program) in line with the vision to eliminate Tuberculosis by 2025.

The transforming growth factor beta (TGF-β) superfamily is a large family of structurally related cell regulatory proteins that was named after its first member, TGF-β1.

Background and Objective: Many clinical trials conducted in the western population have shown that the addition of Rituximab to CHOP regimen provided a higher response rate and excellent early survival in follicular lymphoma. This study aimed to assess the tolerability to Rituximab-CHOP regimen for Follicular lymphoma in Indian population. Methods: From January 2015 to January 2016, 32 patients with histopathologically proven denovo follicular lymphoma who were prescribed. Rituximab-CHOP regimen once every 21 days for 6-8 cycles were included in the study.